JAZZ - Jazz Pharmaceuticals

-

$undefined

N/A

(N/A)

Jazz Pharmaceuticals NasdaqGS:JAZZ Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Xyrem for the treatment of cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Defitelio to treat severe veno-occlusive disease; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab in Phase 3 trial to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Epidiolex in Phase 3 trial to treat LGS, DS, and TSC; Suvecaltamide in Phase 2 trial to treat Parkinson's disease tremor; JZP815, a pan-RAF kinase inhibitor in Phase 1 trial that targets components of the mitogen-activated protein kinase; JZP898, a conditionally activated interferon alpha molecule in Phase 1 trial; JZP441 in Phase 1 trial to treat narcolepsy, IH, and other sleep disorders; JZP324, an extended-release low sodium oxybate formulation in Phase 1 trial for patients with sleep disorders; and JZP150 to treat post-traumatic stress disorder. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.

Location: Waterloo Exchange, Dublin, D04 E5W7, Ireland | Website: https://www.jazzpharma.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

9.52B

Cash

2.572B

Avg Qtr Burn

N/A

Short % of Float

9.97%

Insider Ownership

2.86%

Institutional Own.

99.90%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Xywav (JZP-258) (oxybate salts) Details
EDS in Idiopathic Hypersomnia

Approved

Quarterly sales

EPIDIOLEX® (cannabidiol) Details
Epilepsy, Dravet syndrome, Tuberous sclerosis complex, Lennox-Gastaut syndrome

Approved

Quarterly sales

Zepzelca (Lurbinectedin) Details
Cancer, Small cell lung cancer

Approved

Quarterly sales

Ziihera® (zanidatamab-hrii) Details
Cancer, HER2-expressing cancers, Biliary Tract Cancer

Approved

Quarterly sales

Rylaze /Enrylaze (JZP-458) Details
Acute lymphoblastic leukemia

Approved

Quarterly sales

Phase 3

Data readout

EPIDIOLEX® (cannabidiol) Details
Rare diseases, Neurological disorder, Rare genetic disease, Epilepsy, Seizures

Phase 3

Data readout

Zanidatamab (HER2) Details
Cancer, Cholangiocarcinoma, Gastroesophageal adenocarcinomas

Big Mover™

Susp. Mover™

Phase 3

Data readout

Zanidatamab combo w/ chemo Details
Cancer, HER2-expressing cancers, Gastroesophageal adenocarcinomas

Phase 3

Data readout

Zepzelca + atezolizumab (Tecentriq®) Details
Extensive-stage small cell lung cancer (ES-SCLC)

Phase 3

Data readout

Zepzelca + Irinotecan Details
Relapsed small cell lung cancer (SCLC)

Phase 3

Update

Phase 2b

Update

Phase 2

Data readout

Phase 2

Data readout

CBDV (Cannabidivarin /GWP42006) Details
Epilepsy, Autism spectrum disorders

Phase 2

Data readout

Ziihera + chemotherapy Details
HER2-positive advanced or metastatic gastroesophageal adenocarcinoma (mGEA)

Phase 2

Data readout

Phase 2a

Data readout

Zepzelca (Lurbinectedin) Details
Solid tumor/s, Cancer, Endometrial cancer

Phase 1/2

Data readout

Phase 1/2

Data readout

Zanidatamab combo w/ docetaxel Details
Cancer, HER2-expressing cancers

Phase 1/2

Interim update

JZP351 (CPX-351) Details
Acute myeloid leukemia, Blood cancer, Cancer

Phase 1b

Data readout

JZP815 Details
Solid tumor/s, Cancer

Phase 1

Data readout

Zanidatamab Details
Cancer, Breast cancer

Phase 1

Data readout

JZP441 (orexin-2 receptor agonist) Details
Sleeping disorder, EDS in Idiopathic Hypersomnia , Narcolepsy

Phase 1

Update

JZP898 Details
Solid tumor/s, Cancer

Phase 1

Initiation

EPIDIOLEX® (cannabidiol) Details
Rare diseases, Rare genetic disease, Rett syndrome, Neurological disorder

Failed

Discontinued

JZP-150 (FAAH inhibitor) Details
Post-traumatic stress disorder

Failed

Discontinued

Nabiximols Details
Multiple sclerosis

Failed

Discontinued